Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    amolyt
Previous Study | Return to List | Next Study

AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05239221
Recruitment Status : Active, not recruiting
First Posted : February 14, 2022
Last Update Posted : May 13, 2022
Sponsor:
Information provided by (Responsible Party):
Amolyt Pharma

Brief Summary:

This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)

The protocol includes 3 parts:

  • Part A: first-in-human single ascending dose (SAD) study in healthy volunteers
  • Part B: multiple ascending dose (MAD) study with 2 weeks of treatment in healthy volunteers
  • Part C: open-label MAD study with a total treatment duration of 3 months in patients with cHP.

Condition or disease Intervention/treatment Phase
Chronic Hypoparathyroidism Drug: AZP-3601 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Part C is open label
Primary Purpose: Treatment
Official Title: A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism
Actual Study Start Date : September 7, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AZP-3601
s.c. administration once daily
Drug: AZP-3601
Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection

Placebo Comparator: Placebo (Parts A and B)
s.c. administration once daily
Drug: Placebo
Saline solution visually matching active medication




Primary Outcome Measures :
  1. Treatment Emergent Adverse Events (TEAEs) [ Time Frame: up to 2 weeks (Parts A and B), up to 3 months (Part C) ]
    Number of TEAEs as assessed by medDRA


Secondary Outcome Measures :
  1. Plasma concentration of AZP-3601 [ Time Frame: Day 1 (all Parts), Day 14 (Parts B and C), Day 28 (Part C) ]
  2. Serum calcium [ Time Frame: up to 2 weeks (Parts A and B), up to 3 months (Part C) ]
  3. Serum phosphorus [ Time Frame: up to 2 weeks (Parts A and B), up to 3 months (Part C) ]
  4. s-CTx [ Time Frame: up to 2 weeks (Part B), up to 3 months (Part C) ]
    serum carboxy-terminal telopeptide of type I collagen (bone turnover biomarker)

  5. P1NP [ Time Frame: up to 2 weeks (Part B), up to 3 months (Part C) ]
    serum procollagen type 1 amino-terminal propeptide (bone turnover biomarker)

  6. Daily dose of oral calcium and active vitamin D (Part C) [ Time Frame: up to 3 months (Part C) ]

Other Outcome Measures:
  1. Urinary Calcium levels [ Time Frame: up to 2 weeks (Parts A and B), up to 3 months (Part C) ]
    Levels of urinary calcium



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Main inclusion criteria

  • Part A: healthy male volunteers aged 18 to 60 years inclusive with a Body mass index of 19 to 28 kg/m2
  • Part B: healthy male and female volunteers (non-child bearing potential) aged 18 to 60 years inclusive with a Body mass index of 19 to 28 kg/m2
  • Part C:

    1. Male and female patients aged 18 to 75 years inclusive
    2. History of cHP for ≥12 months at the time of screening with documentation of two measurements of serum calcium and parathyroid hormone (PTH).
    3. Requirement for therapy with calcitriol ≥0.25 μg per day or alphacalcidol ≥0.50 μg per day (both are active vitamin D supplements), and requirement for supplemental oral calcium treatment ≥1000 mg per day over and above normal dietary calcium intake at baseline assessments.

Main exclusion criteria

  • Parts A and B:

    1. Clinically significant abnormal lab values, as judged by the investigator
    2. Using tobacco products with 3 months prior to first drug administration
    3. History of alcohol abuse or drug addiction
  • Part C

    1. Known history of autosomal-dominant hypocalcemia (ADH resulting from gain-of-function calcium-sensing receptor [CaSR] or GNA11 mutations) or pseudohypoparathyroidism (impaired responsiveness to PTH)
    2. Any current disease that might affect calcium metabolism or calcium phosphate homeostasis other than HP
    3. Use of medications such as loop and thiazide diuretics, raloxifene hydrochloride, lithium, methotrexate, cardiac glycosides (e.g., digoxin or digitoxin) or systemic corticosteroids within 4 weeks prior to start of treatment.
    4. Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34), or abaloparatide, within 3 months prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05239221


Locations
Layout table for location information
Hungary
Amolyt Pharma Investigational Site Hungary
Budapest, Hungary
Netherlands
PRA-EDS
Groningen, Netherlands, 9728
Sponsors and Collaborators
Amolyt Pharma
Layout table for additonal information
Responsible Party: Amolyt Pharma
ClinicalTrials.gov Identifier: NCT05239221    
Other Study ID Numbers: AZP-3601-CLI-001
First Posted: February 14, 2022    Key Record Dates
Last Update Posted: May 13, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoparathyroidism
Parathyroid Diseases
Endocrine System Diseases